Key facts
- Teiko.bio’s last known valuation is $45.6M (Oct 2021).
- It has raised $11.6M across 1 recorded rounds; the latest was Early Stage VC ($11.6M) in Sep 2021.
- Notable investors include Western Technology Investment, HOF Capital, Hawktail, Tau Ventures, EPIC Ventures — 9 tracked in total.
- Teiko.bio has filed 1 Form D with the SEC, most recently Oct 2021 ($11.6M sold to 40 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Teiko.bio
Funding rounds
1 roundsAbout Teiko.bio
Developer of a multi-parameter cytometry service platform designed to support global clinical trials. The company's platform offers blood preservation kits for clinical sample collection, cytometry panels, data, and reports through spreadsheets of cytometry data, and tailored gating services, enabling clinicians to gain cytometry insights for clinical trials.
- Sector
- Healthcare
- HQ
- Salt Lake City, UT, United States
- Founded
- 2020
- Employees
- 15
- Website
- teiko-labs.com/
- Ownership
- Privately Held (backing)
Teiko.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Teiko.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Teiko.bio in its N-PORT filings yet. We sweep new filings monthly.